Researcher profile
Edward Chesney
Affiliations
Organizations
Public evidence
11 connected articles
Acceptability of cannabidiol as a treatment for people at clinical high risk for psychosis2026 · medRxivDoes cannabidiol reduce the adverse effects of cannabis in schizophrenia? A randomised, double-blind, cross-over trial.2025 · Europe PMCAre reasons for first using cannabis associated with subsequent cannabis consumption (standard THC units) and psychopathology?2025 · Europe PMCAssessing Cannabis Use in People with Psychosis.2024 · Europe PMCExploring the relationship between frequent cannabis use, belief updating under uncertainty and psychotic-like symptoms.2024 · Europe PMCCannabidiol does not attenuate acute delta-9-tetrahydrocannabinol-induced attentional bias in healthy volunteers: A randomised, double-blind, cross-over study.2024 · Europe PMCInfluence of cannabis use on incidence of psychosis in people at clinical high risk.2023 · Europe PMCThe acute effects of cannabis with and without cannabidiol in adults and adolescents: A randomised, double-blind, placebo-controlled, crossover experiment.2023 · PubMed Central Open AccessDoes cannabidiol make cannabis safer? A randomised, double-blind, cross-over trial of cannabis with four different CBD:THC ratios.2023 · Europe PMCCannabidiol (CBD) as a novel treatment in the early phases of psychosis.2022 · Europe PMCAcceptability of cannabidiol in patients with psychosis.2022 · Europe PMC
Registered research
Connected studies
Do Adolescents and Adults Differ in Their Acute Subjective, Behavioural and Neural Responses to Cannabis, With and Without Cannabidiol?nct04851392Does Cannabidiol Attenuate the Acute Effects of ∆9-tetrahydrocannabinol Intoxication in Individuals Diagnosed With Schizophrenia? A Double-blind, Randomised, Placebo-controlled Experimental Studynct04605393Reducing the Harmful Effects of Cannabis Use: Finding the Optimal CBD:THC Rationct05170217
Matched by exact identifiers only. Profile data: Corpus/OpenAlex.